Management of High-Risk Localized Prostate Cancer

Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that...

Full description

Bibliographic Details
Main Authors: Ariel E. Marciscano, Matthew E. Hardee, Nicholas Sanfilippo
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:Advances in Urology
Online Access:http://dx.doi.org/10.1155/2012/641689
id doaj-a789e3a9e9e94dea99bfd282fdd243a1
record_format Article
spelling doaj-a789e3a9e9e94dea99bfd282fdd243a12020-11-25T00:06:42ZengHindawi LimitedAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/641689641689Management of High-Risk Localized Prostate CancerAriel E. Marciscano0Matthew E. Hardee1Nicholas Sanfilippo2Department of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USADepartment of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USADepartment of Radiation Oncology, NYU School of Medicine, New York, NY 10016, USATraditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that men with high-risk features who are treated in a multimodal fashion at the time of initial diagnosis have improved overall survival. Advances in local treatments such as dose-escalated radiotherapy in conjunction with androgen suppression and postprostatectomy adjuvant radiotherapy have also demonstrated benefits to this subset of patients. However, therapeutic enhancement with the addition of chemotherapy to the primary treatment regimen may help achieve optimal disease control.http://dx.doi.org/10.1155/2012/641689
collection DOAJ
language English
format Article
sources DOAJ
author Ariel E. Marciscano
Matthew E. Hardee
Nicholas Sanfilippo
spellingShingle Ariel E. Marciscano
Matthew E. Hardee
Nicholas Sanfilippo
Management of High-Risk Localized Prostate Cancer
Advances in Urology
author_facet Ariel E. Marciscano
Matthew E. Hardee
Nicholas Sanfilippo
author_sort Ariel E. Marciscano
title Management of High-Risk Localized Prostate Cancer
title_short Management of High-Risk Localized Prostate Cancer
title_full Management of High-Risk Localized Prostate Cancer
title_fullStr Management of High-Risk Localized Prostate Cancer
title_full_unstemmed Management of High-Risk Localized Prostate Cancer
title_sort management of high-risk localized prostate cancer
publisher Hindawi Limited
series Advances in Urology
issn 1687-6369
1687-6377
publishDate 2012-01-01
description Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that men with high-risk features who are treated in a multimodal fashion at the time of initial diagnosis have improved overall survival. Advances in local treatments such as dose-escalated radiotherapy in conjunction with androgen suppression and postprostatectomy adjuvant radiotherapy have also demonstrated benefits to this subset of patients. However, therapeutic enhancement with the addition of chemotherapy to the primary treatment regimen may help achieve optimal disease control.
url http://dx.doi.org/10.1155/2012/641689
work_keys_str_mv AT arielemarciscano managementofhighrisklocalizedprostatecancer
AT matthewehardee managementofhighrisklocalizedprostatecancer
AT nicholassanfilippo managementofhighrisklocalizedprostatecancer
_version_ 1725420860373729280